What is RiconPharma?
Founded in 2008 and headquartered in Denville, New Jersey, RiconPharma operates a sophisticated 10,000-square-foot R&D facility. The company distinguishes itself through the development of novel drug delivery mechanisms, alternative administration routes, and modified-release dosage forms. By focusing on product enhancement and technical optimization, RiconPharma serves as a vital partner for pharmaceutical firms seeking to extend the market viability of their existing portfolios. Its market position is defined by high-barrier technical expertise in formulation science and regulatory-compliant product development.
How much funding has RiconPharma raised?
RiconPharma has raised a total of $2M across 2 funding rounds:
Debt
$1M
Debt
$1M
Debt (2020): $1M with participation from PPP
Debt (2021): $998K led by PPP
Key Investors in RiconPharma
PPP
Public-Private Partnership
What's next for RiconPharma?
With the recent infusion of capital, RiconPharma is positioned to scale its laboratory capabilities and accelerate its proprietary research initiatives. The strategic allocation of these funds will likely focus on expanding the firm's intellectual property portfolio and enhancing its capacity for complex formulation projects. As the pharmaceutical industry continues to prioritize patient-centric delivery methods, RiconPharma's focus on modified-release technologies aligns with broader market trends toward improved therapeutic outcomes and increased drug efficacy. The company is expected to leverage this financial backing to solidify its footprint in the competitive New Jersey biotech corridor and pursue further collaborative ventures with global pharmaceutical partners.
See full RiconPharma company page
